Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Major Depressive Disorder
Clinical trial register · United States · industry-sponsored

Major Depressive Disorder Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 28 Florida 22 Georgia 18 Massachusetts 13 Illinois 13
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Major Depressive Disorder trials in the USA

30 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
BioLite, Inc.
Phase 1/2
12
California
2027-01-15
Not yet open
Bristol-Myers Squibb
Phase 2
200
Arizona, Arkansas, California, Florida, Georgia, Maryland, Massachusetts, New York
2026-10-30
Recruiting
Motif Neurotech, Inc.
Not applicable
20
Georgia, Iowa
2026-09
Recruiting
Definium Therapeutics US, Inc.
Phase 3
165
Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri
2026-05-10
By invitation
NeuroQore Inc.
Not applicable
37
California
2026-01-15
Recruiting
Syndeio Biosciences, Inc
Phase 2
164
Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts
2026-01-05
Recruiting
AbbVie
Phase 2
195
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Nevada
2025-12-18
Recruiting
Neurocrine Biosciences
Phase 4
100
Arkansas, California, Florida, Georgia, Illinois, Nebraska, Ohio, Texas
2025-08-29
Recruiting
Neurocrine Biosciences
Phase 3
550
California, Connecticut, Florida, Iowa, Louisiana, Missouri, New Mexico, New York
2025-08-18
By invitation
Cybin IRL Limited
Phase 3
468
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-07-18
Active, closed
Xenon Pharmaceuticals Inc.
Phase 3
450
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2025-07-08
Recruiting
Neurocrine Biosciences
Phase 3
200
California, Colorado, Connecticut, Florida, Maryland, New York, North Carolina, Pennsylvania
2025-05-30
Recruiting
Neurocrine Biosciences
Phase 3
850
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Maryland, Massachusetts
2025-04-16
Active, closed
Definium Therapeutics US, Inc.
Phase 3
149
Arkansas, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Missouri
2025-04-14
Recruiting
Neurocrine Biosciences
Phase 3
200
Alabama, Arkansas, California, Florida, Georgia, Massachusetts, Missouri, New York
2025-03-31
Active, closed
Xenon Pharmaceuticals Inc.
Phase 3
460
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland
2025-03-18
By invitation
Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions
NCT06823024Obsessive Compulsive Disorder (OCD), Bipolar Disorders, Major Depressive Disorder, Post-Traumatic Stress Disorder, PTSD
Psyrin Inc.
Observational
200
California, New York
2025-02-18
Recruiting
Syndeio Biosciences, Inc
Phase 2
164
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2025-02-03
Recruiting
Neurocrine Biosciences
Phase 3
200
Arkansas, California, Florida, Massachusetts, New York, Ohio, Texas, Washington
2025-01-22
Active, closed
Xenon Pharmaceuticals Inc.
Phase 3
450
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho, Illinois
2024-12-20
Active, closed
Cybin IRL Limited
Phase 3
220
Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2024-12-17
Recruiting
Autobahn Therapeutics, Inc.
Phase 2
230
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts
2024-09-20
By invitation
Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry
NCT06512324Major Depressive Disorder, MDD, Generalized Anxiety Disorder, GAD
Biomedical Discoveries and Neuroscientific Foundations LLC
Observational
5,000
California, Texas
2024-06-27
Recruiting
Axsome Therapeutics, Inc.
Phase 4
350
California, Florida, Georgia, Illinois, Kansas, Louisiana, Massachusetts, Missouri
2023-12-27
By invitation
Kernel
Observational
540
California, Ohio, Washington
2023-08-14
Recruiting
Study of ALTO-300 in MDD
NCT05922878Major Depressive Disorder
Alto Neuroscience
Phase 2
321
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2023-06-08
Recruiting
Intra-Cellular Therapies, Inc.
Phase 3
470
Alabama, California, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri
2023-05-02
Active, closed
Open Label Optimization Study
NCT05819021Major Depressive Disorder
Magnus Medical
Observational
1,000
California, Massachusetts, New York, Washington
2023-04-06
Active, closed
COMPASS Pathways
Phase 2
102
California, Florida, Maryland, Massachusetts, Texas
2023-01-30
Active, closed
Fisher Wallace Neurostimulation & Depression Study
NCT04541563Major Depressive Disorder
ProofPilot
Not applicable
175
New York
2020-08-24
Rows per page Showing 1–30 of 30
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/major-depressive-disorder

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 30 of those studies listing the condition Major Depressive Disorder.

How many Major Depressive Disorder trials are recruiting in the US?

15 of the 30 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 2 have not yet opened recruitment, 8 are active but closed to new participants, and 5 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Major Depressive Disorder), 30 studies
PhaseStudiesRecruitingShare
Phase 313743.3%
Phase 27523.3%
Observational4013.3%
Not applicable3110%
Phase 4226.7%
Phase 1/2103.3%

Most active sponsors

Lead sponsors with the most studies (Major Depressive Disorder)
Lead sponsorStudiesRecruiting
Neurocrine Biosciences66
Xenon Pharmaceuticals Inc.30
Cybin IRL Limited20
Definium Therapeutics US, Inc.21
Syndeio Biosciences, Inc22
AbbVie11
Alto Neuroscience11
Autobahn Therapeutics, Inc.11
Axsome Therapeutics, Inc.11
BioLite, Inc.10

Top states

Top states (Major Depressive Disorder), by number of studies with a site there
StateStudies
California28
Florida22
Georgia18
Illinois13
Massachusetts13
Arkansas12
Connecticut10
Arizona9
Maryland9
New York8
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.